| ||||||||||||||
|
|
|||||||||||||

*Department of Anesthesiology and Critical Care Medicine, OLV Clinic, Aalst, Belgium; and
General Biometric Services and Consulting, Ghent, Belgium
Address correspondence and reprint requests to Guy Cammu, MD, PhD, Department of Anesthesiology and CCM, OLV Clinic, Moorselbaan 164, 9300 Aalst, Belgium. Address e-mail to guy.cammu{at}olvz-aalst.be.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
The anesthesiologists involved were aware that a study was being performed on residual paralysis. Intraoperative variables under examination included the monitoring of neuromuscular transmission (NMT), the pharmacological reversal of neuromuscular blockade, and the use of clinical criteria before tracheal extubation. The clinical criteria were those used in daily practice, at the discretion of the individual anesthesiologist.
Immediately after the patients' arrival in the postanesthetic care unit (PACU), a study nurse recorded their tympanic temperatures and the acceleromyographic responses of their adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve (TOF-Watch®; NV Organon, Oss, The Netherlands). A TOF of 90% was used as cut-off value to exclude residual paralysis (3). Within the first 5 min after arrival in the PACU, the following clinical tests and signs were assessed by a second study nurse who was blinded as to the TOF data: the patient's inability to smile, swallow and speak; general muscular weakness; inability to lift the head for 5 s, to lift the leg for 5 s, inability to sustain a hand grip for 5 s; and inability to perform the sustained tongue depressor test (resisting the removal of a spatula from between the clenched teeth).
The ability of a clinical test to predict residual paralysis (TOF <90%) was described by sensitivity, specificity, and positive and negative predictive values. By giving one point for a positive test result and zero for a negative result, a maximum sum of eight could be obtained for each patient. The ability of each possible sum to predict residual paralysis (TOF <90%) was then described by sensitivity and specificity. Mean variables were compared by the Wilcoxon two-sample test. Contingency tables were analyzed with a
2 test. Values of P < 0.05 were considered statistically significant. Data are expressed as mean ± sd or % (n).
| Results |
|---|
|
|
|---|
The different NMBD used intraoperatively and the management of residual paralysis are shown in Table 1. The most frequently selected NMBD were mivacurium (50%) for outpatients and rocuronium (44%) and atracurium (36%) for inpatients. The methods used to determine and treat residual paralysis did not differ between the outpatient and inpatient groups. In almost half of the patients clinical criteria were used before tracheal extubation, followed by pharmacological reversal, NMT monitoring, or a combination of these.
|
The incidence of residual paralysis was 38% in the outpatient group and 47% in the inpatient group (P = 0.001). In the outpatient group, 43 patients (14%) had a TOF <70%; 78 (24%) had a TOF between 70% and 90%. In the inpatient group, 57 (18%) had a TOF <70%, whereas 92 (29%) had a TOF between 70% and 90%. Mean tympanic temperature was 36°C ± 0.7°C in outpatients and 35.5°C ± 0.9°C in inpatients (P < 0.00001) (Table 1). Three hypothermic inpatients arrived tracheally intubated in the PACU.
One inpatient required reintubation in the PACU. In all patients in whom NMT monitoring had been used but residual paralysis was observed, NMT monitoring had been qualitative (visual or tactile).
The results of the clinical tests made after arrival in the PACU for patients with a TOF
90% are shown in Table 2. A positive test result indicates an inability to smile, swallow and speak; general muscular weakness, etc. Table 3 shows the sensitivity and specificity, as well as the positive and negative predictive values, for a TOF <90%, of each clinical test used in the PACU to detect residual paralysis. "General weakness" was the most sensitive but had the highest negative predictive value. "Inability to sustain hand grip" was the most specific test, and the "inability to perform the sustained tongue depressor test" had the highest positive predictive value. For every clinical test, the specificity and the negative predictive values were more than 62%, and the sensitivity and the positive predictive values were <53%.
|
|
The sum of clinical test results predicting a TOF <90% is shown in Table 4. By combining the tests, the maximum sensitivity for the detection of residual paralysis was 46%, whereas specificity decreased progressively from 94% to 67%.
|
| Discussion |
|---|
|
|
|---|
None of the methods used to determine and treat residual paralysis could prohibit residual paralysis (Table 1). For all patients in whom residual paralysis was observed despite NMT monitoring, the records showed that NMT monitoring had been qualitative. This finding is consistent with previous studies (9,10). Quantitative NMT monitoring can detect residual paralysis in the PACU; therefore, its use during surgery may be recommended.
The sensitivity and the positive predictive values of the clinical tests studied in the PACU were low, and such tests therefore have a low ability to predict residual paralysis as measured by a quantitative TOF%. A combination of clinical tests did not increase the sensitivity for the detection of residual paralysis. However, the clinical tests studied here indicate that neuromuscular weakness can persist even with a TOF
90% (Table 2). Although the outcome of these tests is influenced by the degree of consciousness and postoperative pain (4), it seems logical to attribute at least part of the problem to NMBD.
In conclusion, residual paralysis is frequent in outpatients, although its incidence is less frequent than in inpatients, probably because of the use of shorter-acting NMBD. Qualitative NMT monitoring, pharmacological reversal and clinical tests did not adequately predict residual paralysis. Only quantitative NMT monitoring might prevent residual paralysis. Previous studies in inpatients, especially with longer-acting NMBD, have demonstrated morbidity because of residual paralysis. Such outcomes have not yet been determined in outpatients receiving intermediate- or short-acting blockers and need to be more fully evaluated.
We would like to thank Els De Paepe, MSc, for her assistance.
| Footnotes |
|---|
Presented, in part, at the Annual Meeting of the Society of Anesthesia and Resuscitation of Belgium, Brussels, November 27, 2004, and at the ESA Annual Meeting, Vienna, Austria, May 30, 2005.
Supported, in part, by a grant from Organon.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Eikermann, S. Zaremba, A. Malhotra, A. S. Jordan, C. Rosow, and N. L. Chamberlin Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing Br. J. Anaesth., September 1, 2008; 101(3): 344 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Murphy, J. W. Szokol, J. H. Marymont, S. B. Greenberg, M. J. Avram, and J. S. Vender Residual Neuromuscular Blockade and Critical Respiratory Events in the Postanesthesia Care Unit Anesth. Analg., July 1, 2008; 107(1): 130 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Miller Sugammadex May Replace Best Clinical Practice: A Misconception Anesth. Analg., November 1, 2007; 105(5): 1507 - 1507. [Full Text] [PDF] |
||||
![]() |
M. Naguib, A. F. Kopman, and J. E. Ensor Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis Br. J. Anaesth., March 1, 2007; 98(3): 302 - 316. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|